Drug Insights

Unlock the Power of Synapse: A Guide to Searching Doxycycline hyclate

23 February 2024
2 min read

Doxycycline hyclate, marketed under the brand name Vibramycin, is a type of antibiotic drug belonging to the tetracycline class. The original manufacturer of doxycycline hyclate was Pfizer, who first developed the medication and obtained FDA approval in 1967 for the treatment of various bacterial infections. Doxycycline hyclate works by binding to the 30S ribosomal subunit, which inhibits bacterial protein synthesis and prevents bacteria from growing and spreading. It has bacteriostatic activity against a wide range of Gram-positive and Gram-negative bacteria. This medication is available in different forms, including tablets, capsules, and syrup, for oral administration. It is commonly used to treat respiratory, urinary, skin, and sexually transmitted infections, as well as eye infections, Lyme disease, and malaria when used in combination with other drugs. Click on the image below to begin the exploration journey of Doxycycline hyclate through the Synapse database!

图形用户界面, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Innovent's Phase 3 RESTORE-1 Study of IBI311 for Thyroid Eye Disease Hits Key Goal, Eyes NMPA Filing
Latest Hotspot
3 min read
Innovent's Phase 3 RESTORE-1 Study of IBI311 for Thyroid Eye Disease Hits Key Goal, Eyes NMPA Filing
23 February 2024
Innovent Reveals Key Goal Achieved in Phase 3 Study (RESTORE-1) of IBI311 (IGF-1R-Targeting Agent) for Thyroid Eye Condition, Intends to File for Approval with NMPA.
Read →
Decoding Infigratinib: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GU
Decoding Infigratinib: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GU
23 February 2024
2024 ASCO_GU presented new trial data on infigratinib, an FGFR3 inhibitor, showing promise in clinical use.
Read →
Bayer Initiates Phase II Trial of New Anti-alpha2 Antiplasmin Drug for Deep Vein Thrombosis
Latest Hotspot
3 min read
Bayer Initiates Phase II Trial of New Anti-alpha2 Antiplasmin Drug for Deep Vein Thrombosis
23 February 2024
Bayer commences a second-stage trial using a novel anti-alpha2 antiplasmin agent in individuals affected by deep venous clots.
Read →
How to Effectively Search for BuSpar on Synapse
Drug Insights
2 min read
How to Effectively Search for BuSpar on Synapse
23 February 2024
BuSpar® (buspirone hydrochloride) is an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.